Celltrion, Inc. 068270

INCHEON, South Korea, August 24, 2026--Celltrion expands its Omlyclo® portfolio in Europe by launching the 300 mg strength in PFS and AI presentations.

Celltrion, Inc. today announced that seven abstracts will be presented at the 2026 Digestive Disease Week® (DDW) Annual Meeting, taking place May 2-5 in Chicago, Illinois. The oral and poster presentations will feature data including post-hoc analysis of its pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of ZYMFENTRA®, the first and only FDA-approved subcutaneous infliximab.

Celltrion, Inc. today announced that AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation is now commercially available to patients in the United States.

Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today presented key strategic priorities and clinical development updates for its innovative drug pipelines including antibody-drug conjugates (ADCs) and multi-specific antibodies (msAbs) at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California. The company also highlighted plans to expand its manufacturing and R&D capabilities to support long-term growth, enhance supply resilience and reinforce its

Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today announced that Jin-Seok Seo, Chief Executive Officer and Hyuk-Jae Lee, Senior Executive Vice President at Celltrion, will present at the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California on January 12–15, 2026.

FDA clearance enables initiation of Abpro’s first clinical-stage solid tumor program Clinical trial anticipated to commence in the first half of 2026 through Abpro’s global collaboration with Celltrion BURLINGTON, Mass. and INCHEON, South Korea, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP), a biotechnology company developing next-generation antibody therapeutics for solid tumors, today announced, together with its co-development partner Celltrion, Inc., that the U.S. Food

IND submitted for ABP-102/CT-P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable safety profile ABP-102/CT-P72 represents Abpro’s first IND submission for a phase 1 trial in a solid tumor indication, and is being co-developed by Abpro and Celltrion, Inc. BURLINGTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP, “Abpro”), a biotechnology company developing novel breakthrough therapeutics for so

As global markets navigate a complex landscape marked by a tech sell-off and concerns over elevated valuations, particularly in artificial intelligence spending, investor sentiment has been further dampened by the longest U.S. federal government shutdown on record and rising job cuts. In this environment, identifying high-growth tech stocks with strong fundamentals and global potential becomes crucial for investors seeking opportunities amidst broader market volatility.

Kaigene Inc., a U.S.-based biotechnology company pioneering next-generation antibody therapeutics for autoimmune disorders, announced today that it has entered into an exclusive global licensing agreement with Celltrion Inc., a leading global biopharmaceutical company, for two of Kaigene's nonclinical-stage assets, KG006 and KG002.